Steris Plc (STE) has been underperforming compared to its competitors despite daily gains. Yet, it is deemed a good proposition for retention in portfolios, with a 3% rise since the last earnings report. Financial services are showing considerable interest in Steris as Commonwealth Equity Services hold a $7.21 million position. However, Rhumbline Advisers have reduced their holdings. The company shows promise with strategic SWOT insight and estimates for Q2 2025 earnings. Steris presented at the Morgan Stanley Healthcare Conference and has seen a 63% return over the last five years. Insider Sale occurred recently, indicating possible concerns within the company's management. Meanwhile, their stock hits a new 52-week high after an analyst upgrade. Steris' AST business expansion and new offerings are aiding its growth, alongside decent Q1 earnings with an operating margin fall. Forecasts suggest Q3 2026 earnings of $2.60 per share. Major transactions include the sale of Steris's dental unit to HuFriedy, helping the company focus on debt reduction.
Steris Plc STE News Analytics from Wed, 20 Jan 2016 08:00:00 GMT to Sat, 07 Sep 2024 12:46:59 GMT -
Rating 4
- Innovation 7
- Information 5
- Rumor -2
